

350. Reddy S, Factor SA, Molho ES, Feustel PJ: The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. *Mov Disord* 2002; 17:676–681 [G]
351. Workman RH Jr, Orengo CA, Bakey AA, Molinari VA, Kunik ME: The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. *J Neuropsychiatry Clin Neurosci* 1997; 9:594–597 [B]
352. Marsh L, Lyketsos C, Reich SG: Olanzapine for the treatment of psychosis in patients with Parkinson's disease and dementia. *Psychosomatics* 2001; 42:477–481 [B]
353. Walker Z, Grace J, Overshot R, Satarasinghe S, Swan A, Katona CL, McKeith IG: Olanzapine in dementia with Lewy bodies: a clinical study. *Int J Geriatr Psychiatry* 1999; 14:459–466 [B]
354. Marsh L, McDonald WM, Cummings J, Ravina B: Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group. *Mov Disord* 2006; 21:148–158 [G]
355. Guo Z, Fratiglioni L, Zhu L, Fastbom J, Winblad B, Viitanen M: Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. *Arch Neurol* 1999; 56:991–996 [C]
356. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, Laks T, Lilov E, Moisseiev V, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Fagard R: Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. *Lancet* 1998; 352:1347–1351 [A]
357. Malouf R, Birks J: Donepezil for vascular cognitive impairment. *Cochrane Database Syst Rev* 2004; (1):CD004395 [E]
358. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV: Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. *Lancet* 2002; 359:1283–1290 [A]
359. Erkinjuntti T: Diagnosis and management of vascular cognitive impairment and dementia. *J Neural Transm Suppl* 2002; (63):91–109 [G]
360. Nyenhuis DL, Gorelick PB: Vascular dementia: a contemporary review of epidemiology, diagnosis, prevention, and treatment. *J Am Geriatr Soc* 1998; 46:1437–1448 [G]
361. McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ: Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. *Arch Neurol* 2001; 58:1803–1809 [G]
362. Litvan I: Therapy and management of frontal lobe dementia patients. *Neurology* 2001; 56:S41–S45 [G]
363. Radin L, Radin G: *What If It's Not Alzheimer's? A Caregiver's Guide to Dementia*. Amherst, NY, Prometheus Books, 2003 [G]
364. Rice DP, Fox PJ, Max W, Webber PA, Lindeman DA, Hauck WW, Segura E: The economic burden of Alzheimer's disease care. *Health Aff (Millwood)* 1993; 12:164–176 [G]
365. Smith GE, Kokmen E, O'Brien PC: Risk factors for nursing home placement in a population-based dementia cohort. *J Am Geriatr Soc* 2000; 48:519–525 [D]
366. Boss P, Caron W, Horbal J, Mortimer J: Predictors of depression in caregivers of dementia patients: boundary ambiguity and mastery. *Fam Process* 1990; 29:245–254 [G]
367. Schulz R, Beach SR: Caregiving as a risk factor for mortality: the Caregiver Health Effects Study. *JAMA* 1999; 282:2215–2219 [C]
368. Vitaliano PP, Zhang J, Scanlan JM: Is caregiving hazardous to one's physical health? A meta-analysis. *Psychol Bull* 2003; 129:946–972 [E]
369. Dura JR, Stukenberg KW, Kiecolt-Glaser JK: Chronic stress and depressive disorders in older adults. *J Abnorm Psychol* 1990; 99:284–290 [D]
370. Covinsky KE, Newcomer R, Fox P, Wood J, Sands L, Dane K, Yaffe K: Patient and caregiver characteristics associated with depression in caregivers of patients with dementia. *J Gen Intern Med* 2003; 18:1006–1014 [G]
371. Schulz R, Burgio L, Burns R, Eisdorfer C, Gallagher-Thompson D, Gitlin LN, Mahoney DF: Resources for Enhancing Alzheimer's Caregiver Health (REACH): overview, site-specific outcomes, and future directions. *Gerontologist* 2003; 43:514–520 [B]
372. Schulz R, Mendelsohn AB, Haley WE, Mahoney D, Allen RS, Zhang S, Thompson L, Belle SH: End-of-life care and the effects of bereavement on family caregivers of persons with dementia. *N Engl J Med* 2003; 349:1936–1942 [G]
373. Chan DC, Kasper JD, Black BS, Rabins PV: Presence of behavioral and psychological symptoms predicts nursing home placement in community-dwelling elders with cognitive impairment in univariate but not multivariate analysis. *J Gerontol A Biol Sci Med Sci* 2003; 58:548–554 [C]
374. Rovner BW, German PS, Broadhead J, Morriss RK, Brant LJ, Blaustein J, Folstein MF: The prevalence and management of dementia and other psychiatric disorders in nursing homes. *Int Psychogeriatr* 1990; 2:13–24 [G]
375. Magaziner J, German P, Zimmerman SI, Hebel JR, Burton L, Gruber-Baldini AL, May C, Kittner S: The prevalence of dementia in a statewide sample of new nursing home admissions aged 65 and older: diagnosis by expert panel. *Epidemiology of Dementia in Nursing Homes Research Group. Gerontologist* 2000; 40:663–672 [G]
376. Tariot PN, Podgorski CA, Blazina L, Leibovici A: Mental disorders in the nursing home: another perspective. *Am J Psychiatry* 1993; 150:1063–1069 [G]
377. Rosenblatt A, Samus QM, Steele CD, Baker AS, Harper MG, Brandt J, Rabins PV, Lyketsos CG: The Mary-

- land Assisted Living Study: prevalence, recognition, and treatment of dementia and other psychiatric disorders in the assisted living population of central Maryland. *J Am Geriatr Soc* 2004; 52:1618–1625 [G]
378. Sloane PD, Barrick AL: Improving long-term care for persons with Alzheimer's disease. *J Am Geriatr Soc* 1996; 44:91–92 [G]
379. Teri L, Huda P, Gibbons L, Young H, van Leynseele J: STAR: a dementia-specific training program for staff in assisted living residences. *Gerontologist* 2005; 45:686–693 [A–]
380. Testad I, Aasland AM, Aarsland D: The effect of staff training on the use of restraint in dementia: a single-blind randomised controlled trial. *Int J Geriatr Psychiatry* 2005; 20:587–590 [A–]
381. Lawton MP, Brody EM, Saperstein AR: A controlled study of respite service for caregivers of Alzheimer's patients. *Gerontologist* 1989; 29:8–16 [B]
382. Pynoos J, Regnier V: Improving residential environments for frail elderly: bridging the gap between theory and application, in *The Concept and Measurement of Quality of Life in the Frail Elderly*. Edited by Birren JE, Lubben JE, Cichowlas Rowe J, Deutchman DE. San Diego, CA, Academic Press, 1991, pp 91–119 [G]
383. Reimer MA, Slaughter S, Donaldson C, Currie G, Eliasziw M: Special care facility compared with traditional environments for dementia care: a longitudinal study of quality of life. *J Am Geriatr Soc* 2004; 52:1085–1092 [C]
384. Sullivan-Marx EM, Strumpf NE, Evans LK, Baumgarten M, Maislin G: Predictors of continued physical restraint use in nursing home residents following restraint reduction efforts. *J Am Geriatr Soc* 1999; 47:342–348 [B]
385. Castle NG, Fogel B: Characteristics of nursing homes that are restraint free. *Gerontologist* 1998; 38:181–188 [G]
386. Tinetti ME, Liu WL, Marottoli RA, Ginter SF: Mechanical restraint use among residents of skilled nursing facilities: prevalence, patterns, and predictors. *JAMA* 1991; 265:468–471 [G]
387. Katz IR: Optimizing atypical antipsychotic treatment strategies in the elderly. *J Am Geriatr Soc* 2004; 52:S272–S277 [F]
388. Fossey J, Ballard C, Juszcak E, James I, Alder N, Jacoby R, Howard R: Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. *BMJ* 2006; 332:756–761 [A–]
389. Inouye SK: Delirium in older persons. *N Engl J Med* 2006; 354:1157–1165 [F]
390. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: clinical characterization and outcome. *Arch Neurol* 1999; 56:303–308 [C]
391. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli M, Hampel H, Scheltens P, Tierney MC, Whitehouse P, Winblad B: Mild cognitive impairment. *Lancet* 2006; 367:1262–1270 [G]
392. Geldmacher DS: Differential diagnosis of dementia syndromes. *Clin Geriatr Med* 2004; 20:27–43 [G]
393. Ross GW, Bowen JD: The diagnosis and differential diagnosis of dementia. *Med Clin North Am* 2002; 86:455–476 [G]
394. Geerlings MI, Schoevers RA, Beekman AT, Jonker C, Deeg DJ, Schmand B, Ader HJ, Bouter LM, Van Tilburg W: Depression and risk of cognitive decline and Alzheimer's disease: results of two prospective community-based studies in The Netherlands. *Br J Psychiatry* 2000; 176:568–575 [C]
395. Steffens DC, Otey E, Alexopoulos GS, Butters MA, Cuthbert B, Ganguli M, Geda YE, Hendrie HC, Krishnan RR, Kumar A, Lopez OL, Lyketsos CG, Mast BT, Morris JC, Norton MC, Peavy GM, Petersen RC, Reynolds CF, Salloway S, Welsh-Bohmer KA, Yesavage J: Perspectives on depression, mild cognitive impairment, and cognitive decline. *Arch Gen Psychiatry* 2006; 63:130–138 [G]
396. Modrego PJ, Ferrandez J: Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: a prospective cohort study. *Arch Neurol* 2004; 61:1290–1293 [C]
397. Ritchie K, Artero S, Touchon J: Classification criteria for mild cognitive impairment: a population-based validation study. *Neurology* 2001; 56:37–42 [G]
398. Kawas C, Katzman R: Epidemiology of dementia and Alzheimer's disease, in *Alzheimer Disease*, 2nd ed. Edited by Terry RD, Katzman R, Bick KL, Sisodia SS. Philadelphia, PA, Lippincott Williams & Wilkins, 1999, pp 95–116 [G]
399. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR: Brain infarction and the clinical expression of Alzheimer disease: the Nun Study. *JAMA* 1997; 277:813–817 [C]
400. de la Torre JC: Alzheimer disease as a vascular disorder: nosological evidence. *Stroke* 2002; 33:1152–1162 [G]
401. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL: A new clinical scale for the staging of dementia. *Br J Psychiatry* 1982; 140:566–572 [G]
402. Reisberg B, Ferris SH, de Leon MJ, Crook T: The Global Deterioration Scale for assessment of primary degenerative dementia. *Am J Psychiatry* 1982; 139:1136–1139 [G]
403. Sclan SG, Reisberg B: Functional assessment staging (FAST) in Alzheimer's disease: reliability, validity, and ordinality. *Int Psychogeriatr* 1992; 4(suppl 1):55–69 [G]
404. Geerlings MI, Jonker C, Bouter LM, Ader HJ, Schmand B: Association between memory complaints and incident Alzheimer's disease in elderly people with normal baseline cognition. *Am J Psychiatry* 1999; 156:531–537 [C]

405. Jorm AF, Christensen H, Korten AE, Jacomb PA, Henderson AS: Memory complaints as a precursor of memory impairment in older people: a longitudinal analysis over 7–8 years. *Psychol Med* 2001; 31:441–449 [C]
406. Schofield PW, Marder K, Dooneief G, Jacobs DM, Sano M, Stern Y: Association of subjective memory complaints with subsequent cognitive decline in community-dwelling elderly individuals with baseline cognitive impairment. *Am J Psychiatry* 1997; 154:609–615 [C]
407. Auer SR, Sclan SG, Yaffee RA, Reisberg B: The neglected half of Alzheimer disease: cognitive and functional concomitants of severe dementia. *J Am Geriatr Soc* 1994; 42:1266–1272 [G]
408. Souren LE, Franssen EH, Reisberg B: Contractures and loss of function in patients with Alzheimer's disease. *J Am Geriatr Soc* 1995; 43:650–655 [G]
409. Hebert LE, Scherr PA, Beckett LA, Albert MS, Pilgrim DM, Chown MJ, Funkenstein HH, Evans DA: Age-specific incidence of Alzheimer's disease in a community population. *JAMA* 1995; 273:1354–1359 [C]
410. Petersen RC: Mild cognitive impairment as a diagnostic entity. *J Intern Med* 2004; 256:183–194 [G]
411. Knopman DS: Dementia and cerebrovascular disease. *Mayo Clin Proc* 2006; 81:223–230 [G]
412. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, Copeland JR, Dartigues JF, Jagger C, Martinez-Lage J, Soininen H, Hofman A, Neurologic Diseases in the Elderly Research Group: Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. *Neurology* 2000; 54:S4–S9 [G]
413. Knopman DS, Rocca WA, Cha RH, Edland SD, Kokmen E: Incidence of vascular dementia in Rochester, Minn, 1985–1989. *Arch Neurol* 2002; 59:1605–1610 [G]
414. Knopman DS, Parisi JE, Boeve BF, Cha RH, Apaydin H, Salviati A, Edland SD, Rocca WA: Vascular dementia in a population-based autopsy study. *Arch Neurol* 2003; 60:569–575 [G]
415. Jellinger KA: Alzheimer disease and cerebrovascular pathology: an update. *J Neural Transm* 2002; 109:813–836 [G]
416. Jellinger KA: Vascular-ischemic dementia: an update. *J Neural Transm Suppl* 2002; (62):1–23 [G]
417. Chui HC, Mack W, Jackson JE, Mungas D, Reed BR, Tinklenberg J, Chang FL, Skinner K, Tasaki C, Jagust WJ: Clinical criteria for the diagnosis of vascular dementia: a multicenter study of comparability and interrater reliability. *Arch Neurol* 2000; 57:191–196 [G]
418. Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R: Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. *Neurology* 1992; 42:473–480 [G]
419. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, Moody DM, O'Brien MD, Yamaguchi T, Grafman J, Drayer BP, Bennett DA, Fisher M, Ogata J, Kokmen E, Bermejo F, Wolf PA, Gorelick PB, Bick KL, Pajean AK, Bell MA, DeCarli C, Culebras A, Korczyn AD, Bogousslavsky J, Hartmann A, Scheinberg P: Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. *Neurology* 1993; 43:250–260 [G]
420. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P: Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. *Arch Neurol* 2003; 60:387–392 [C]
421. McKeith IG, Fairbairn AF, Perry RH, Thompson P: The clinical diagnosis and misdiagnosis of senile dementia of Lewy body type (SDLT). *Br J Psychiatry* 1994; 165:324–332 [G]
422. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londo E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. *Neurology* 2005; 65:1863–1872 [G]
423. Shergill S, Mullan E, D'Ath P, Katona C: What is the clinical prevalence of Lewy body dementia? *Int J Geriatr Psychiatry* 1994; 9:907–912 [G]
424. Barber R, Panikkar A, McKeith IG: Dementia with Lewy bodies: diagnosis and management. *Int J Geriatr Psychiatry* 2001; 16(suppl 1):S12–S18 [F]
425. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF: Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. *Neurology* 1998; 51:1546–1554 [G]
426. Blass DM, Hatanpaa KJ, Brandt J, Rao V, Steinberg M, Troncoso JC, Rabins PV: Dementia in hippocampal sclerosis resembles frontotemporal dementia more than Alzheimer disease. *Neurology* 2004; 63:492–497 [D]
427. Togo T, Isojima D, Akatsu H, Suzuki K, Uchikado H, Katsuse O, Iseki E, Kosaka K, Hirayasu Y: Clinical features of argyrophilic grain disease: a retrospective survey of cases with neuropsychiatric symptoms. *Am J Geriatr Psychiatry* 2005; 13:1083–1091 [G]
428. Lishman WA: *Organic Psychiatry: The Psychological Consequences of Cerebral Disorder*, 3rd ed. Oxford, UK, Blackwell Publishing, 1998 [G]
429. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, Mohs RC, Thal LJ, Whitehouse PJ,

- DeKosky ST, Cummings JL: Practice parameter: management of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2001; 56:1154–1166 [G]
430. Rogers JC, Holm MB, Burgio LD, Granieri E, Hsu C, Hardin JM, McDowell BJ: Improving morning care routines of nursing home residents with dementia. *J Am Geriatr Soc* 1999; 47:1049–1057 [A–]
431. Gormley N, Lyons D, Howard R: Behavioural management of aggression in dementia: a randomized controlled trial. *Age Ageing* 2001; 30:141–145 [A–]
432. Beck CK, Vogelpohl TS, Rasin JH, Urriri JT, O'Sullivan P, Walls R, Phillips R, Baldwin B: Effects of behavioral interventions on disruptive behavior and affect in demented nursing home residents. *Nurs Res* 2002; 51:219–228 [A–]
433. Weiner MF, Tractenberg RE, Sano M, Logsdon R, Teri L, Galasko D, Gamst A, Thomas R, Thal LJ: No long-term effect of behavioral treatment on psychotropic drug use for agitation in Alzheimer's disease patients. *J Geriatr Psychiatry Neurol* 2002; 15:95–98 [B]
434. Burgio L: Interventions for the behavioral complications of Alzheimer's disease: behavioral approaches. *Int Psychogeriatr* 1996; 8(suppl 1):45–52 [G]
435. Gatz M, Fiske A, Fox LS, Kaskie B, Kasl-Godley JE, McCallum TJ, Wetherell JL: Empirically validated psychological treatments for older adults. *Journal of Mental Health and Aging* 1998; 4:9–46 [F]
436. Teri L, Logsdon RG, Uomoto J, McCurry SM: Behavioral treatment of depression in dementia patients: a controlled clinical trial. *J Gerontol B Psychol Sci Soc Sci* 1997; 52:159–166 [A–]
437. Teri L, Logsdon RG, Schindler RJ: Treatment of behavioral and mood disturbances in dementia. *Generations: Journal of the American Society on Aging* 1999; 23:50–56 [F]
438. Burnside I, Haight B: Reminiscence and life review: therapeutic interventions for older people. *Nurse Pract* 1994; 19:55–61 [F]
439. Jones GM: Validation therapy: a companion to reality orientation. *Can Nurse* 1985; 81:20–23 [G]
440. Feil N: V/F Validation: The Feil Method: How to Help Disoriented Old-Old. Cleveland, OH, Edward Feil Productions, 1992 [G]
441. Group for the Advancement of Psychiatry Committee on Aging: The Psychiatric Treatment of Alzheimer's Disease: Report 125. New York, Brunner/Mazel, 1988 [G]
442. Robichaud L, Hebert R, Desrosiers J: Efficacy of a sensory integration program on behaviors of inpatients with dementia. *Am J Occup Ther* 1994; 48:355–360 [A–]
443. Woods P, Ashley J: Simulated presence therapy: using selected memories to manage problem behaviors in Alzheimer's disease patients. *Geriatr Nurs* 1995; 16:9–14 [B]
444. Scanland SG, Emershaw LE: Reality orientation and validation therapy: dementia, depression, and functional status. *J Gerontol Nurs* 1993; 19:7–11 [B]
445. Schrijnemaekers V, van Rossum E, Candel M, Frederiks C, Derix M, Sielhorst H, van den BP: Effects of emotion-oriented care on elderly people with cognitive impairment and behavioral problems. *Int J Geriatr Psychiatry* 2002; 17:926–937 [A–]
446. Neal M, Briggs M: Validation therapy for dementia. *Cochrane Database Syst Rev* 2003; (3):CD001394 [E]
447. Chung JC, Lai CK, Chung PM, French HP: Snoezelen for dementia. *Cochrane Database Syst Rev* 2002; (4):CD003152 [E]
448. Woods B, Spector A, Jones C, Orrell M, Davies S: Reminiscence therapy for dementia. *Cochrane Database Syst Rev* 2005; (2):CD001120 [E]
449. Powell-Proctor L, Miller E: Reality orientation: a critical appraisal. *Br J Psychiatry* 1982; 140:457–463 [F]
450. Tappen RM: The effect of skill training on functional abilities of nursing home residents with dementia. *Res Nurs Health* 1994; 17:159–165 [B]
451. Hanley IG, McGuire RJ, Boyd WD: Reality orientation and dementia: a controlled trial of two approaches. *Br J Psychiatry* 1981; 138:10–14 [A–]
452. Koh K, Ray R, Lee J, Nair A, Ho T, Ang PC: Dementia in elderly patients: can the 3R mental stimulation programme improve mental status? *Age Ageing* 1994; 23:195–199 [B]
453. Johnson CH, McLaren SM, McPherson FM: The comparative effectiveness of three versions of 'classroom' reality orientation. *Age Ageing* 1981; 10:33–35 [B]
454. Woods RT: Reality orientation and staff attention: a controlled study. *Br J Psychiatry* 1979; 134:502–507 [A–]
455. Brook P, Degun G, Mather M: Reality orientation, a therapy for psychogeriatric patient: a controlled study. *Br J Psychiatry* 1975; 127:42–45 [B]
456. Greene JG, Timbury GC, Smith R, Gardiner M: Reality orientation with elderly patients in the community: an empirical evaluation. *Age Ageing* 1983; 12:38–43 [B]
457. Reeve W, Ivison D: Use of environmental manipulation and classroom and modified informal reality orientation with institutionalized, confused elderly patients. *Age Ageing* 1985; 14:119–121 [B]
458. Williams R, Reeve W, Ivison D, Kavanagh D: Use of environmental manipulation and modified informal reality orientation with institutionalized, confused elderly subjects: a replication. *Age Ageing* 1987; 16:315–318 [B]
459. Gerber GJ, Prince PN, Snider HG, Atchison K, Dubois L, Kilgour JA: Group activity and cognitive improvement among patients with Alzheimer's disease. *Hosp Community Psychiatry* 1991; 42:843–845 [A–]
460. Baldelli MV, Pirani A, Motta M, Abati E, Mariani E, Manzi V: Effects of reality orientation therapy on elder-

- ly patients in the community. *Arch Gerontol Geriatr* 1993; 7:211–218 [B]
461. Quayhagen MP, Quayhagen M, Corbeil RR, Roth PA, Rodgers JA: A dyadic remediation program for care recipients with dementia. *Nurs Res* 1995; 44:153–159 [A]
 462. Cahn-Weiner DA, Malloy PF, Rebok GW, Ott BR: Results of a randomized placebo-controlled study of memory training for mildly impaired Alzheimer's disease patients. *Appl Neuropsychol* 2003; 10:215–223 [A–]
 463. Beck C, Heacock P, Mercer S, Thatcher R, Sparkman C: The impact of cognitive skills remediation training on persons with Alzheimer's disease or mixed dementia. *J Geriatr Psychiatry* 1988; 21:73–88 [A–]
 464. Zarit SH, Zarit JM, Reever KE: Memory training for severe memory loss: effects on senile dementia patients and their families. *Gerontologist* 1982; 22:373–377 [A–]
 465. Yesavage JA, Westphal J, Rush L: Senile dementia: combined pharmacologic and psychologic treatment. *J Am Geriatr Soc* 1981; 29:164–171 [A–]
 466. McEvoy CL, Patterson RL: Behavioral treatment of deficit skills in dementia patients. *Gerontologist* 1986; 26:475–478 [B]
 467. Abraham IL, Reel SJ: Cognitive nursing interventions with long-term care residents: effects on neurocognitive dimensions. *Arch Psychiatr Nurs* 1992; 6:356–365 [B]
 468. Koger SM, Chapin K, Brotons M: Is music therapy an effective intervention for dementia? a meta-analytic review of literature. *J Music Ther* 1999; 36:2–15 [E]
 469. Baker R, Bell S, Baker E, Gibson S, Holloway J, Pearce R, Dowling Z, Thomas P, Assey J, Wareing LA: A randomized controlled trial of the effects of multi-sensory stimulation (MSS) for people with dementia. *Br J Clin Psychol* 2001; 40:81–96 [A–]
 470. Baker R, Holloway J, Holtkamp CC, Larsson A, Hartman LC, Pearce R, Scherman B, Johansson S, Thomas PW, Wareing LA, Owens M: Effects of multi-sensory stimulation for people with dementia. *J Adv Nurs* 2003; 43:465–477 [A–]
 471. Ballard CG, O'Brien JT, Reichelt K, Perry EK: Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa. *J Clin Psychiatry* 2002; 63:553–558 [A]
 472. Snow LA, Hovanec L, Brandt J: A controlled trial of aromatherapy for agitation in nursing home patients with dementia. *J Altern Complement Med* 2004; 10:431–437 [A]
 473. Lazowski DA, Ecclestone NA, Myers AM, Paterson DH, Tudor-Locke C, Fitzgerald C, Jones G, Shima N, Cunningham DA: A randomized outcome evaluation of group exercise programs in long-term care institutions. *J Gerontol A Biol Sci Med Sci* 1999; 54:M621–M628 [A]
 474. Tappen RM, Roach KE, Applegate EB, Stowell P: Effect of a combined walking and conversation intervention on functional mobility of nursing home residents with Alzheimer disease. *Alzheimer Dis Assoc Disord* 2000; 14:196–201 [A]
 475. Cott CA, Dawson P, Sidani S, Wells D: The effects of a walking/talking program on communication, ambulation, and functional status in residents with Alzheimer disease. *Alzheimer Dis Assoc Disord* 2002; 16:81–87 [A]
 476. Pomeroy VM, Warren CM, Honeycombe C, Briggs RS, Wilkinson DG, Pickering RM, Steiner A: Mobility and dementia: is physiotherapy treatment during respite care effective? *Int J Geriatr Psychiatry* 1999; 14:389–397 [A]
 477. Teri L, Logsdon RG: Identifying pleasant activities for Alzheimer's disease patients: the pleasant events schedule-AD. *Gerontologist* 1991; 31:124–127 [G]
 478. Karlsson I, Brane G, Melin E, Nyth AL, Rybo E: Effects of environmental stimulation on biochemical and psychological variables in dementia. *Acta Psychiatr Scand* 1988; 77:207–213 [B]
 479. Lawton MP, Van Haitsma K, Klapper J, Kleban MH, Katz IR, Corn J: A stimulation-retreat special care unit for elders with dementing illness. *Int Psychogeriatr* 1998; 10:379–395 [A–]
 480. Birks J: Cholinesterase inhibitors for Alzheimer's disease. *Cochrane Database Syst Rev* 2006; (1):CD005593 [E]
 481. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR: Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. *J Am Geriatr Soc* 2003; 51:937–944 [B]
 482. Schneider LS, Qizilbash N: Delay in nursing home placement with donepezil. *J Am Geriatr Soc* 2004; 52:1024–1026 [G]
 483. Schneider LS: AD2000: donepezil in Alzheimer's disease. *Lancet* 2004; 363:2100–2101 [G]
 484. Black S, Roman GC, Geldmacher DS, Salloway S, Hecker J, Burns A, Perdomo C, Kumar D, Pratt R: Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. *Stroke* 2003; 34:2323–2330 [A]
 485. Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, Pratt RD: Donepezil in vascular dementia: a randomized, placebo-controlled study. *Neurology* 2003; 61:479–486 [A]
 486. Auchus AP, Brashear H, Salloway S, Schelteris P, Korczyn A, Gassman-Mayer C, Gold M: Results of a trial of galantamine in subjects with vascular dementia confirmed by central MRI reading. Poster presented at the 56th annual meeting of the American Academy of Neurology, San Francisco, CA, April 24–May 1, 2004 [A]
 487. McShane R, Schneider LS: Meta-analysis of memantine: summary and commentary on the Cochrane Col-

- laboration's systematic review. *Alzheimer's and Dementia* 2005; 1:67–71 [E]
488. Halliwell B, Gutteridge JMC: Oxygen radicals in the nervous system. *Trends Neurosci* 1985; 8:22–26 [G]
 489. Behl C, Davis J, Cole GM, Schubert D: Vitamin E protects nerve cells from amyloid beta protein toxicity. *Biochem Biophys Res Commun* 1992; 186:944–950 [G]
 490. Sano M, Ernesto C, Klauber MR, Schafer K, Woodbury P, Thomas R, Grundman M, Growdon J, Thal LJ: Rationale and design of a multicenter study of selegiline and alpha-tocopherol in the treatment of Alzheimer disease using novel clinical outcomes: Alzheimer's Disease Cooperative Study. *Alzheimer Dis Assoc Disord* 1996; 10:132–140 [G]
 491. Aisen PS, Davis KL: Inflammatory mechanisms in Alzheimer's disease: implications for therapy. *Am J Psychiatry* 1994; 151:1105–1113 [G]
 492. Sherwin BB: Estrogenic effects on memory in women. *Ann N Y Acad Sci* 1994; 743:213–230 [G]
 493. Fillit H, Weinreb H, Cholst I, Luine V, McEwen B, Amador R, Zabriskie J: Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. *Psychoneuroendocrinology* 1986; 11:337–345 [B]
 494. Ohkura T, Isse K, Akazawa K, Hamamoto M, Yaoi Y, Hagino N: Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type: 7 case reports. *Dementia* 1995; 6:99–107 [G]
 495. Henderson VW, Paganini-Hill A, Emanuel CK, Dunn ME, Buckwalter JG: Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and nondemented control subjects. *Arch Neurol* 1994; 51:896–900 [D]
 496. Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, Andrews H, Mayeux R: Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. *Lancet* 1996; 348:429–432 [C]
 497. Oken BS, Storzbach DM, Kaye JA: The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. *Arch Neurol* 1998; 55:1409–1415 [E]
 498. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF, North American EGB Study Group: A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. *JAMA* 1997; 278:1327–1332 [A]
 499. Crapper McLachlan DR, Dalton AJ, Kruck TP, Bell MY, Smith WL, Kalow W, Andrews DF: Intramuscular desferrioxamine in patients with Alzheimer's disease. *Lancet* 1991; 337:1304–1308 [B]
 500. Cardelli MB, Russell M, Bagne CA, Pomara N: Chelation therapy: unproved modality in the treatment of Alzheimer-type dementia. *J Am Geriatr Soc* 1985; 33:548–551 [G]
 501. Cherny RA, Barnham KJ, Lynch T, Volitakis I, Li QX, McLean CA, Multhaup G, Beyreuther K, Tanzi RE, Masters CL, Bush AI: Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease. *J Struct Biol* 2000; 130:209–216 [G]
 502. Satterlee WG, Reams SG, Burns PR, Hamilton S, Tran PV, Tollefson GD: A clinical update on olanzapine treatment in schizophrenia and in elderly Alzheimer's disease patients. *Psychopharmacol Bull* 1995; 31:534 [G]
 503. Scharre DW, Chang SI: Cognitive and behavioral effects of quetiapine in Alzheimer disease patients. *Alzheimer Dis Assoc Disord* 2002; 16:128–130 [B]
 504. McManus DQ, Arvanitis LA, Kowalczyk BB, Seroquel Trial 48 Study Group: Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. *J Clin Psychiatry* 1999; 60:292–298 [B]
 505. Fujikawa T, Takahashi T, Kinoshita A, Kajiyama H, Kurata A, Yamashita H, Yamawaki S: Quetiapine treatment for behavioral and psychological symptoms in patients with senile dementia of Alzheimer type. *Neuropsychobiology* 2004; 49:201–204 [B]
 506. Ballard C, Margallo-Lana M, Juszcak E, Douglas S, Swann A, Thomas A, O'Brien J, Everatt A, Sadler S, Maddison C, Lee L, Bannister C, Elvish R, Jacoby R: Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. *BMJ* 2005; 330:874 [A]
 507. Breder C, Swanink R, Marcus R, Kostic S, Iwamoto T, Carson W, McQuade R: Dose-ranging study of aripiprazole in patients with dementia of Alzheimer's disease. Poster presented at the 9th International Conference on Alzheimer's Disease and Related Disorders, Philadelphia, PA, July 17–22, 2004 [A]
 508. Streim J, Breder C, Swanink R, McQuade R, Iwamoto T, Carson W: Flexible dose aripiprazole in psychosis of Alzheimer's dementia (AD). Poster presented at the 157th annual meeting of the American Psychiatric Association, New York, May 1–6, 2004 [A]
 509. Salzman C, Vaccaro B, Lieff J, Weiner A: Clozapine in older patients with psychosis and behavioral disturbances. *Am J Geriatr Psychiatry* 1995; 3:26–33 [G]
 510. Woerner MG, Alvir JM, Kane JM, Saltz BL, Lieberman JA: Neuroleptic treatment of elderly patients. *Psychopharmacol Bull* 1995; 31:333–337 [B]
 511. Jeste DV, Caligiuri MP, Paulsen JS, Heaton RK, Lacro JP, Harris MJ, Bailey A, Fell RL, McAdams LA: Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 outpatients. *Arch Gen Psychiatry* 1995; 52:756–765 [B]
 512. Salzman C: Treatment of the elderly agitated patient. *J Clin Psychiatry* 1987; 48(May suppl):19–22 [G]
 513. Jeste DV, Okamoto A, Napolitano J, Kane JM, Martinez RA: Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. *Am J Psychiatry* 2000; 157:1150–1155 [B]
 514. Jeste DV, Lacro JP, Bailey A, Rockwell E, Harris MJ, Caligiuri MP: Lower incidence of tardive dyskinesia

- with risperidone compared with haloperidol in older patients. *J Am Geriatr Soc* 1999; 47:716–719 [C]
515. Ertugrul A, Demir B: Clozapine-induced tardive dyskinesia: a case report. *Prog Neuropsychopharmacol Biol Psychiatry* 2005; 29:633–635 [G]
 516. Hasan S, Buckley P: Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. *Am J Psychiatry* 1998; 155:1113–1116 [F]
 517. Philibert RA, Adam LA, Frank FM, Carney-Doebbeling C: Olanzapine usage associated with neuroleptic malignant syndrome. *Psychosomatics* 2001; 42:528–529 [G]
 518. Sing KJ, Ramaekers GM, Van Harten PN: Neuroleptic malignant syndrome and quetiapine. *Am J Psychiatry* 2002; 159:149–150 [G]
 519. Murty RG, Mistry SG, Chacko RC: Neuroleptic malignant syndrome with ziprasidone. *J Clin Psychopharmacol* 2002; 22:624–626 [G]
 520. Chakraborty N, Johnston T: Aripiprazole and neuroleptic malignant syndrome. *Int Clin Psychopharmacol* 2004; 19:351–353 [G]
 521. Wooltorton E: Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. *CMAJ* 2002; 167:1269–1270 [E]
 522. US Food and Drug Administration: MedWatch: 2003 Safety Alerts for Drugs, Biologics, Medical Devices, and Dietary Supplements: Risperdal (Risperidone), 2003. <http://www.fda.gov/medwatch/SAFETY/2003/safety03.htm#risper> [G]
 523. US Food and Drug Administration: 2004 Safety Alert: Zyprexa (olanzapine), March 1, 2004. <http://www.fda.gov/medwatch/SAFETY/2004/zyprexa.htm> [G]
 524. Schneider LS, Tariot PN, Mintzer J, Minkwitz M, Zhong K: Cerebrovascular adverse events and quetiapine: a pooled analysis in elderly patients with dementia. Paper presented at the 18th annual meeting of the American Association for Geriatric Psychiatry, San Diego, CA, March 3–6, 2005 [E]
 525. Schneider LS, Dagerman KS, Insel P: Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. *JAMA* 2005; 294:1934–1943 [E]
 526. Ballard C, Grace J, McKeith I, Holmes C: Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. *Lancet* 1998; 351:1032–1033 [D]
 527. Tariot PN, Schneider LS, Katz IR, Mintzer JE, Street JS: Quetiapine in nursing home residents with Alzheimer's dementia and psychosis (abstract). *Am J Geriatr Psychiatry* 2002; 10(suppl 1):93 [A]
 528. Devanand DP, Sackeim HA, Brown RP, Mayeux R: A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease. *Arch Neurol* 1989; 46:854–857 [B]
 529. Beber CR: Management of behavior in the institutionalized aged. *Dis Nerv Syst* 1965; 26:591–595 [A–]
 530. Delemos GP, Clement WR, Nickels E: Effects of diazepam suspension in geriatric patients hospitalized for psychiatric illnesses. *J Am Geriatr Soc* 1965; 13:355–359 [A–]
 531. Lott AD, McElroy SL, Keys MA: Valproate in the treatment of behavioral agitation in elderly patients with dementia. *J Neuropsychiatry Clin Neurosci* 1995; 7:314–319 [G]
 532. Mellow AM, Solano-Lopez C, Davis S: Sodium valproate in the treatment of behavioral disturbance in dementia. *J Geriatr Psychiatry Neurol* 1993; 6:205–209 [G]
 533. Porsteinsson AP, Tariot PN, Erb R, Gaile S: An open trial of valproate for agitation in geriatric neuropsychiatric disorders. *Am J Geriatr Psychiatry* 1997; 5:344–351 [B]
 534. Herrmann N, Lancot K, Myszak M: Effectiveness of gabapentin for the treatment of behavioral disorders in dementia. *J Clin Psychopharmacol* 2000; 20:90–93 [B]
 535. Risse SC, Barnes R: Pharmacologic treatment of agitation associated with dementia. *J Am Geriatr Soc* 1986; 34:368–376 [G]
 536. Kunik ME, Yudofsky SC, Silver JM, Hales RE: Pharmacologic approach to management of agitation associated with dementia. *J Clin Psychiatry* 1994; 55(Feb suppl):13–17 [G]
 537. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A: Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms: a randomized, controlled, open 14-month study. *Eur Neurol* 2003; 49:13–19 [A–]
 538. Ramadan FH, Naughton BJ, Bassanelli AG: Treatment of verbal agitation with a selective serotonin reuptake inhibitor. *J Geriatr Psychiatry Neurol* 2000; 13:56–59 [B]
 539. Swartz JR, Miller BL, Lesser IM, Darby AL: Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. *J Clin Psychiatry* 1997; 58:212–216 [B]
 540. Deakin JB, Rahman S, Nestor PJ, Hodges JR, Sahakian BJ: Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. *Psychopharmacology (Berl)* 2004; 172:400–408 [A]
 541. Lee HB, Lyketsos CG: Depression in Alzheimer's disease: heterogeneity and related issues. *Biol Psychiatry* 2003; 54:353–362 [G]
 542. Ancoli-Israel S, Martin JL, Gehrman P, Shochat T, Corey-Bloom J, Marler M, Nolan S, Levi L: Effect of light on agitation in institutionalized patients with severe Alzheimer disease. *Am J Geriatr Psychiatry* 2003; 11:194–203 [A–]
 543. Richards KC, Sullivan SC, Phillips RL, Beck CK, Overton-McCoy AL: The effect of individualized activities on the sleep of nursing home residents who are cognitively impaired: a pilot study. *J Gerontol Nurs* 2001; 27:30–37 [B]

544. Asayama K, Yamadera H, Ito T, Suzuki H, Kudo Y, Endo S: Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. *J Nippon Med Sch* 2003; 70:334–341 [A]
545. Singer C, Tractenberg RE, Kaye J, Schafer K, Gamst A, Grundman M, Thomas R, Thal LJ: A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. *Sleep* 2003; 26:893–901 [A]
546. Markowitz JS, Gutterman EM, Lilienfeld S, Papadopoulos G: Sleep-related outcomes in persons with mild to moderate Alzheimer disease in a placebo-controlled trial of galantamine. *Sleep* 2003; 26:602–606 [A]
547. Desai AK, Grossberg GT: Diagnosis and treatment of Alzheimer's disease. *Neurology* 2005; 64:S34–S39 [F]
548. Standridge JB: Pharmacotherapeutic approaches to the prevention of Alzheimer's disease. *Am J Geriatr Pharmacother* 2004; 2:119–132 [F]
549. Vasilevko V, Cribbs DH: Novel approaches for immunotherapeutic intervention in Alzheimer's disease. *Neurochem Int* 2006; 49:113–126 [F]
550. Leys D, Henon H, Mackowiak-Cordoliani MA, Pasquier F: Poststroke dementia. *Lancet Neurol* 2005; 4:752–759 [F]
551. Roman GC: Vascular dementia prevention: a risk factor analysis. *Cerebrovasc Dis* 2005; 20(suppl 2):91–100 [F]
552. Buhr GT, White HK: Difficult behaviors in long-term care patients with dementia. *J Am Med Dir Assoc* 2006; 7:180–192 [F]
553. Weisman GD, Kovach C, Cashin SE: Differences in dementia services and settings across place types and regions. *Am J Alzheimers Dis Other Demen* 2004; 19:291–298 [G]
554. Black W, Almeida OP: A systematic review of the association between the behavioral and psychological symptoms of dementia and burden of care. *Int Psychogeriatr* 2004; 16:295–315 [E]

